J. Barret

发表

Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action

B. Hill, B. van Hille, C. Etiévant, 2000, Anti-cancer drugs.

Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3

J. Barret, H. Bazin, P. Mondon, 2017, Molecular Cancer Therapeutics.

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages

G. Massonnet, A. Nicolas, S. Roman-Roman, 2017, Oncotarget.

Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation

J. Barret, J. Prost, M. Salón, 2021, Cancers.

Physalin B, a novel inhibitor of the ubiquitin-proteasome pathway, triggers NOXA-associated apoptosis.

J. Annereau, C. Bailly, L. Créancier, 2008, Biochemical pharmacology.

ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells

J. Barret, J. Prost, A. Pèlegrin, 2019, Cell Communication and Signaling.

F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system.

J. Annereau, C. Bailly, J. Barret, 2008, Cancer research.

Antitumor activity of vinflunine: effector pathways and potential for synergies.

J. Barret, A. Kruczynski, D. Braguer, 2008, Seminars in oncology.

Differential binding to the α/β-tubulin dimer of vinorelbine and vinflunine revealed by nuclear magnetic resonance analyses

B. Hill, J. Barret, A. Milon, 2002 .

Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid.

F. Colpaert, B. Hill, C. Etiévant, 1998, Biochemical pharmacology.

A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.

J. Barret, A. Larsen, P. Calsou, 1994, Molecular pharmacology.

Requirements for P-glycoprotein recognition based on structure-activity relationships in the podophyllotoxin series.

B. Hill, C. Etiévant, J. Barret, 1998, Anti-cancer drug design.

Potential mechanisms of resistance to microtubule inhibitors.

J. Annereau, J. Barret, M. Kavallaris, 2008, Seminars in oncology.

Deficient nucleotide excision repair activity in protein extracts from normal human lymphocytes.

J. Barret, P. Calsou, B. Salles, 1995, Carcinogenesis.

DNA excision-repair synthesis is enhanced in a murine leukemia L1210 cell line resistant to cisplatin.

J. Barret, P. Calsou, B. Salles, 1993, European journal of biochemistry.

Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.

J. Annereau, C. Bailly, L. Créancier, 2007, Biochemical pharmacology.

Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid.

B. Hill, J. Barret, M. Cadou, 2002, Biochemical pharmacology.

Evaluation of DNA repair inhibition by antitumor or antibiotic drugs using a chemiluminescence microplate assay.

B. Hill, J. Barret, C. Provot, 1997, Carcinogenesis.

Safety, Tolerance, and Pharmacokinetics of a Small Unilamellar Liposomal Formulation of Amphotericin B (AmBisome) in Neutropenic Patients

W. Wilson, S. Chanock, J. Barret, 1998, Antimicrobial Agents and Chemotherapy.

The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer

A. Nicolas, S. Roman-Roman, I. Ray-Coquard, 2021, Biology.

Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system

C. Bailly, J. Barret, A. Kruczynski, 2011, Investigational New Drugs.

Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II.

B. Hill, C. Etiévant, J. Barret, 2003, Biochemical pharmacology.

Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases

B. Hill, J. Barret, P. Olive, 2000, British Journal of Cancer.

F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.

B. Hill, B. van Hille, C. Etiévant, 2000, Biochemical pharmacology.

Tumor targeting with radiolabeled integrin alpha(v beta 3) binding RGD peptides in a nude mouse tumor model.

W. Oyen, J. Barret, L. Massuger, 2001 .

Synthesis and biological evaluation of bengacarboline derivatives.

J. Annereau, C. Bailly, J. Barret, 2008, Bioorganic & Medicinal Chemistry Letters.

F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells.

B. Hill, C. Etiévant, J. Barret, 2002, Anticancer research.

Studies of the potency of protein kinase inhibitors on ATPase activities.

G. Ferry, J. Boutin, J. Barret, 1993, Chemico-biological interactions.

Integrated system for the screening of the specificity of protein kinase inhibitors.

G. Ferry, J. Boutin, J. Barret, 1993, Biochemical pharmacology.

Purification and characterization of the major tyrosine protein kinase from the human promyelocytic cell line, HL60.

G. Ferry, J. Boutin, J. Barret, 1993, European journal of biochemistry.

An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II

C. Bailly, J. Barret, E. Käs, 2011, PloS one.

Novel aspects of natural and modified vinca alkaloids.

J. Barret, A. Kruczynski, A. Duflos, 2012, Current medicinal chemistry. Anti-cancer agents.

A fluorescent biomarker of the polyamine transport system to select patients with AML for F14512 treatment.

J. Annereau, C. Bailly, J. Barret, 2010, Leukemia research.

Synthesis of conjugated spermine derivatives with 7-nitrobenzoxadiazole (NBD), rhodamine and bodipy as new fluorescent probes for the polyamine transport system.

J. Annereau, C. Bailly, J. Barret, 2009, Bioorganic & medicinal chemistry letters.

Circulating CD14high CD16low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression

J. Barret, J. Prost, G. Ferron, 2020, Journal for immunotherapy of cancer.

Circulating CD14 high CD16 low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression

J. Barret, J. Prost, G. Ferron, 2020 .

Synthesis of 9-acridinyl sulfur derivatives: sulfides, sulfoxides and sulfones. Comparison of their activity on tumour cells.

Christopher M. Farrell, B. Hill, J. Barret, 2004, European journal of medicinal chemistry.

Vinflunine (20′,20′-difluoro- 3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro

B. Hill, C. Etiévant, J. Barret, 2004, Investigational New Drugs.

The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells

I. Navarro-Teulon, J. Barret, M. Jarlier, 2017, Oncotarget.

Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase

J. Annereau, C. Bailly, A. Marchand, 2009, Anti-cancer drugs.

Decreased Nucleotide Excision Repair Activity and Alterations of Topoisomerase IIα Are Associated with the in Vivo Resistance of a P388 Leukemia Subline to F11782, a Novel Catalytic Inhibitor of Topoisomerases I and II

L. Créancier, B. Hill, B. van Hille, 2004, Clinical Cancer Research.

Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA

J. Annereau, D. Cussac, C. Bailly, 2009, Molecular Cancer Therapeutics.

Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents

B. Hill, C. Etiévant, J. Barret, 2002, Cancer Chemotherapy and Pharmacology.

In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs

B. Hill, C. Etiévant, J. Barret, 2000, Cancer Chemotherapy and Pharmacology.

Substrate phosphorylation capacities of the major tyrosine protein kinase from the human promyelocytic cell line, HL-60.

G. Ferry, J. Boutin, J. Barret, 2009, International journal of peptide and protein research.

Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair.

D. Averbeck, E. Moustacchi, J. Barret, 1994, Carcinogenesis.

Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro

B. Hill, C. Etiévant, J. Barret, 2001, Cancer Chemotherapy and Pharmacology.

Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.

B. Hill, J. Barret, A. Kruczynski, 1999, Anti-cancer drugs.

ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells

J. Barret, J. Prost, A. Pèlegrin, 2019, Cell Communication and Signaling.

DNA repair activity in protein extracts of fresh human malignant lymphoid cells.

J. Barret, G. Laurent, P. Calsou, 1996, Molecular pharmacology.

Variability of airway structure and inflammation in normal subjects and in cases of nonfatal and fatal asthma.

A. James, J. Barret, N. Carroll, 1996, Pathology, research and practice.

Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II.

B. Hill, C. Etiévant, J. Barret, 2000, Anticancer research.